error
Divisa

DRUG-INDUCED LIVER TOXICITY

,
9781493976768 ::  DRUG-INDUCED LIVER TOXICITY
ISBN:

9781493976768

Colección:METHODS IN PHARMACOLOGY AND TOXICOLOGY
EditorialSPRINGER NATURE
Edicion:
Páginas:564
Idioma:INGLES
P.V.P.: 124,99 € + 4% IVA = 129,99 €
Dto 5% Ahorras 6,50 €
Importe final iva incl. 123,49 €
PLAZO DE ENTREGA 15 DIAS

THIS BOOK PROVIDES A COMPREHENSIVE VIEW OF THE METHODOLOGIES USED FOR THE STUDY OF LIVER TOXICITY ENCOUNTERED THROUGHOUT THE WHOLE LIFE CYCLE OF A DRUG, FROM DRUG DISCOVERY, TO CLINICAL TRIAL, POST-MARKETING, AND EVEN CLINICAL PRACTICE. ORGANIZED INTO SIX SECTIONS, THE FIRST SECTION INTRODUCES THE MECHANISMS CONTRIBUTING TO DRUG-INDUCED LIVER TOXICITY.&NBSP; THE SECOND AND THIRD SECTION EXPLORE IN SILICO AND IN VITRO APPROACHES USED TO HELP MITIGATE HEPATOTOXICITY LIABILITY AT THE EARLY STAGES OF DRUG DEVELOPMENT. THE FOURTH SECTION DESCRIBES METHODOLOGIES APPLIED IN REGULATORY PROCESSES, INCLUDING PRECLINICAL STUDIES, CLINICAL TRIALS, AND POST-MARKETING SURVEILLANCE. THE FIFTH SECTION DISCUSSES CLINICAL HEPATOTOXICITY. EMERGING TECHNOLOGIES ARE EXAMINED IN THE FINAL SECTION. AS A VOLUME IN THE METHODS IN PHARMACOLOGY AND TOXICOLOGY SERIES, CHAPTERS INCLUDE THE KIND OF EXPERT ADVICE THAT WILL LEAD TO OPTIMAL RESULTS.&NBSP;<DIV><BR></DIV><DIV>AUTHORITATIVE AND PRACTICAL, <I>DRUG-INDUCED LIVER TOXICITY</I> SERVES ALL THOSE WHO AIM TO IMPROVE ASSESSMENT AND UNDERSTANDING OF HEPATOTOXIC POTENTIALS OF NEW MEDICATIONS AND MARKETED DRUGS.<BR></DIV><DIV><BR></DIV><DIV>CHAPTER 30 IS OPEN ACCESS UNDER A CC BY 4.0 LICENSE VIA LINK.SPRINGER.COM.&NBSP;</DIV><DIV><BR></DIV>

<P><B>PART I: INTRODUCTION</B></P> <P><B>&NBSP;</B></P> <P><B>1. OVERVIEW OF MECHANISMS OF DRUG-INDUCED LIVER INJURY (DILI) AND KEY CHALLENGES IN DILI RESEARCH</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; NABIL NOUREDDIN AND NEIL KAPLOWITZ</P> <P>&NBSP;</P> <P><B>PART II: IN SILICO AND MODELING APPROACHES</B></P> <P><B>&NBSP;</B></P> <P><B>2. DETECTION, ELIMINATION, MITIGATION, AND PREDICTION OF DRUG-INDUCED LIVER INJURY IN DRUG DISCOVERY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; FRANCOIS POGNAN</P> <P>&NBSP;</P> <P><B>3. DRUG-INDUCED LIVER INJURY (DILI) CLASSIFICATION AND ITS APPLICATION ON HUMAN DILI RISK PREDICTION</B></P> &NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; SHRADDHA THAKKAR, MINJUN CHEN, HUIXIAO HONG, ZHICHAO LIU, HONG FANG, AND WEIDA TONG<P></P> <P>&NBSP;</P> <P><B>4. </B><B>PHYSICOCHEMICAL PROPERTIES AND STRUCTURAL ALERTS</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; LILIA FISK, NIGEL GREENE, AND RUSS NAVEN</P> <P>&NBSP;</P> <P><B>5. QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP MODELS FOR PREDICTING RISK OF DRUG-INDUCED LIVER INJURY IN HUMANS</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; HUIXIAO HONG, JIEQIANG ZHU, MINJUN CHEN, PING GONG, CHAOYANG ZHANG, AND WEIDA TONG</P> <P>&NBSP;</P> <P><B>6. AN INTRODUCTION TO DILISYM<SUP>® </SUP>SOFTWARE, A MECHANISTIC MATHEMATICAL REPRESENTATION OF DRUG-INDUCED LIVER INJURY</B></P> &NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CHRISTINA BATTISTA, BRETT A. HOWELL, SCOTT Q. SILER, AND PAUL B. WATKINS<P></P> <P>&NBSP;</P> <P><B>PART III: IN VITRO TECHNOLOGIES</B></P> <P><B>&NBSP;</B></P> <P><B>7. </B><B>PREDICTION OF HUMAN LIVER TOXICITY USING IN VITRO ASSAYS: </B><B>LIMITATIONS AND OPPORTUNITIES</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; FRANCK A. ATIENZAR AND JEAN-MARIE NICOLAS</P> <P>&NBSP;</P> <P><B>8. USE OF LIVER-DERIVED CELL LINES FOR THE STUDY OF DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ZHEN REN, SI CHEN, BAITANG NING, AND LEI GUO</P> <P>&NBSP;</P> <P><B>9. EVALUATION OF DRUG-INDUCED LIVER INJURIES (DILI) WITH HUMAN HEPATOCYTES: SCIENTIFIC RATIONALE AND EXPERIMENTAL APPROACHES</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ALBERT P. LI</P> <P>&NBSP;</P> <P><B>10. </B><B>STATUS AND USE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) IN TOXICITY TESTING</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MIN WEI WONG, CHRIS S. PRIDGEON, CONSTANZE SCHLOTT, B. KEVIN PARK, AND CHRISTOPHER E.P. GOLDRING</P> <P>&NBSP;</P> <P><B>11. ENGINEERED HUMAN LIVER CO-CULTURES FOR INVESTIGATING DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CHASE P. MONCKTON, AND SALMAN R. KHETANI</P> <P>&NBSP;</P> <P><B>12. STATUS AND FUTURE OF 3D CELL CULTURE IN TOXICITY TESTING</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MONICAH A. OTIENO, JINPING GAN, AND WILLIAM PROCTOR</P> <P>&NBSP;</P> <P><B>13. REACTIVE METABOLITE ASSESSMENT IN DRUG DISCOVERY AND DEVELOPMENT IN SUPPORT OF SAFE DRUG DESIGN</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; AXEL PÄHLER</P> <P>&NBSP;</P> <P><B>14. IN VITRO ASSESSMENT OF MITOCHONDRIAL TOXICITY TO PREDICT DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MATHIEU PORCEDDU, NELLY BURON, PIERRE RUSTIN, BERNARD FROMENTY, AND ANNIE BORGNE-SANCHEZ</P> <P>&NBSP;</P> <P><B>15. BILE SALT EXPORT PUMP: DRUG-INDUCED LIVER INJURY AND ASSESSMENT APPROACHES</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; RUITANG DENG</P> <P>&NBSP;</P> <P><B>16. HIGH CONTENT SCREENING FOR PREDICTION OF HUMAN DRUG-INDUCED LIVER INJURY</B></P> &NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MIKAEL PERSSON<P></P> <P>&NBSP;</P> <P><B>17. INTERPRETATION, INTEGRATION, AND IMPLEMENTATION OF IN VITRO ASSAY DATA: THE PREDICTIVE TOXICITY CHALLENGE</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; DEBORAH S. LIGHT, MICHAEL D. ALEO, AND J. GERRY KENNA</P> <P>&NBSP;</P> <P><B>PART IV: METHODOLOGIES APPLIED IN REGULATORY SCIENCE</B></P> <P><B>&NBSP;</B></P> <P><B>18. PERSPECTIVES ON THE REGULATORY AND CLINICAL SCIENCE OF DRUG-INDUCED LIVER INJURY (DILI)</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MARK I. AVIGAN AND MONICA A. MUÑOZ</P> <P>&NBSP;</P> <P><B>19. REGULATORY TOXICOLOGICAL STUDIES: IDENTIFYING DRUG-INDUCED LIVER INJURY USING NONCLINICAL STUDIES</B></P> &NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ELIZABETH HAUSNER AND IMRAN KHAN<P></P> <P>&NBSP;</P> <P><B>20. HY’S LAW AND EDISH FOR CLINICAL STUDIES</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; JOHN SENIOR AND TED GUO</P> <P>&NBSP;</P> <P><B>21. VARIABILITY IN BASELINE LIVER TEST VALUES IN CLINICAL TRIALS: CHALLENGES IN ENHANCING DRUG-INDUCED LIVER INJURY ASSESSMENT IN SUBJECTS WITH LIVER DISEASE</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; BEREKET TESFALDET, GYORGY CSAKO, TEJAS PATEL, MD SHAMSUZZAMAN, AND EILEEN NAVARRO ALMARIO</P> <P>&NBSP;</P> <P><B>22. POSTMARKETING SURVEILLANCE OF DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; S. CHRISTOPHER JONES, CINDY KORTEPETER, AND ALLEN D. BRINKER</P> <P>&NBSP;</P> <P><B>PART V: METHODOLOGIES FOR CLINICAL STUDIES</B></P> <P><B>&NBSP;</B></P> <P><B>23. </B><B>HOST RISK MODIFIERS IN IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) AND ITS INTERPLAY WITH DRUG PROPERTIES</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CAMILLA STEPHENS, M. ISABEL LUCENA, AND RAÚL J. ANDRADE</P> <P>&NBSP;</P> <P><B>24. HUMAN LEUKOCYTE ANTIGEN (HLA) AND OTHER GENETIC RISK FACTORS IN DRUG-INDUCED LIVER INJURY (DILI)</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ANN K. DALY</P> <P>&NBSP;</P> <P><B>25. IMMUNE MECHANISMS IN DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; HARTMUT JAESCHKE AND DEAN J. NAISBITT</P> <P>&NBSP;</P> <P><B>26. </B><B>TRANSLATIONAL AND MECHANISTIC BIOMARKERS OF DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; DANIEL J. ANTOINE</P> <P>&NBSP;</P> <P><B>27. CAUSALITY ASSESSMENT METHODS IN DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ROLF TESCHKE AND GABY DANAN</P> <P>&NBSP;</P> <P><B>PART VI: NEW EMERGING TECHNOLOGIES</B></P> <P><B>&NBSP;</B></P> <P><B>28. CIRCULATING MICRORNAS AS NOVEL BIOMARKERS OF DRUG-INDUCED LIVER INJURY IN HUMANS</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; JULIAN KRAUSKOPF, JOS C. KLEINJANS, AND THEO M. DE KOK</P> <P>&NBSP;</P> <P><B>29. SYSTEMS MICROSCOPY APPROACHES IN UNRAVELING AND PREDICTING DRUG-INDUCED LIVER INJURY (DILI)</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MARIJE NIEMEIJER, STEVEN HIEMSTRA, STEVEN WINK, WOUTER DEN HOLLANDER, BAS TER BRAAK, AND BOB VAN DE WATER</P> <P>&NBSP;</P> <P><B>30. </B><B>NON-INVASIVE PRE-CLINICAL AND CLINICAL IMAGING OF LIVER TRANSPORTER FUNCTION RELEVANT TO DRUG-INDUCED LIVER INJURY</B></P> <P>&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; J. GERRY KENNA, JOHN C. WATERTON, ANDREAS BAUDY, ALEKSANDRA GALETIN, CATHERINE D.G. HINES, PAUL HOCKINGS, MANISHKUMAR PATEL, DANIEL SCOTCHER, STEVEN SOURBRON, SABINA ZIEMIAN, AND GUNNAR SCHUETZ</P>

FARMACOLOGIA
Libros relacionados
ISBN: 9781118047934 THE MERCK INDEXTHE MERCK INDEX
9781118047934
Diciembre 2018

99.37€ S/I
94,40€ S/I

ISBN: 9783319995458 LESSONS ON CAFFEINE, CANNABIS & COLESSONS ON CAFFEINE, CANNABIS & CO
9783319995458
Diciembre 2018

64.99€ S/I
61,74€ S/I

ISBN: 9783319999449 BOTULINUM TOXIN TREATMENTBOTULINUM TOXIN TREATMENT
9783319999449
Diciembre 2018

39.99€ S/I
37,99€ S/I

ISBN: 9789811322501 RECENT TRENDS AND TECHNIQUES IN PLANT METABOLIC ENGINEERINGRECENT TRENDS AND TECHNIQUES IN PLANT ...
9789811322501
Diciembre 2018

149.99€ S/I
142,49€ S/I

ISBN: 9780128104606 HANDBOOK OF PHARMACEUTICAL WET GRANULATIONHANDBOOK OF PHARMACEUTICAL WET ...
9780128104606
Noviembre 2018

200€ S/I
190,00€ S/I